NCT06454383
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
At risk: Primary completion moved at least 4 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 3 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Primary and study completion pushed from Nov 13, 2026 to Mar 23, 2027
- Site details revised
- Notable Eligibility criteria expanded, about 35 words
- Start date: May 13, 2024 to Jun 10, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle and leflunomide PO QD on days -3 to -1 prior to cycle 1 and days 1-28 of each cycle thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive cholestyramine PO TID for 11 days at the end of treatment in the absence of unacceptable toxicity. Patients also undergo CT, MRI, or other imaging scans as clinically indicated throughout the study, as well as blood sample collection on study and during follow up.
Procedures: Biospecimen Collection, Computed Tomography, Diagnostic Imaging, Magnetic Resonance Imaging
Drugs: Cholestyramine, Gemcitabine, Leflunomide
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States